With a distinctive rigid β sheet binding site that is entirely contained within a small single polypeptide structure and derivation from organisms that last shared a common ancestor with humans and other mammals over 500 million years ago, our new class of monoclonal antibodies provide access to targets that are distinct from those accessed with conventional antibodies and can be engineered to execute novel diagnostic and therapeutic functions.

Our new class of monoclonal antibodies are small, single polypeptide antibodies that possess a distinctive rigid β-sheet binding site structure. These antibodies access specificities that are distinct from those of conventional antibodies, including the ability to bind glycans and discriminate closely related glycan structures. The single polypeptide structure facilitates development of novel structures and functions such as multispecific antibodies and antibody polymers for high sensitivity detection and targeting of infectious agents and tumor cells.

Initially developed to facilitate discovery of antibodies that bind to glycans, our multimeric ligand technology has additional uses including cell and/or tissue specific targeting and delivery of modifying agents such as drugs, antibodies, nucleic acids and RNA/DNA modifiers.